A translational study of "Randomized phase II trial evaluating trastuzumab + capecitabine (HX) or lapatinib + capecitabine (LX) in HER2-positive metastatic breast cancer patients previously treated with trastuzumab and taxanes."
Not Applicable
- Conditions
- HER2-positive metastatic breast cancer
- Registration Number
- JPRN-UMIN000006464
- Lead Sponsor
- West Japan Oncology Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Female
- Target Recruitment
- 110
Inclusion Criteria
Not provided
Exclusion Criteria
None
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Searching a biomarker for progression-free survival, response rate and survival time
- Secondary Outcome Measures
Name Time Method